AbstractSerial analysis for the activating JAK2(V617F) mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation.
Figures & Tables
Vol. 91 No. 3 (2006): March, 2006 : Comparative Studies
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com